Inactive Instrument

AVEO Pharmaceuticals, Inc. Share Price

AVEO

US0535883070

Latest news: AVEO Pharmaceuticals, Inc.

23/07	Arcus Biosciences Announces Clinical Supply Agreement with Aveo Oncology to Evaluate Casdatifan in Combination with Tivozanib for Advanced Kidney Cancer Patients	CI
30/06	AVEO Pharmaceuticals, Inc. Announces Executive Changes	CI
30/06	AVEO Pharmaceuticals, Inc. Announces CEO Changes	CI
18/02	AVEO Oncology Announces Completion of the First Interim Analysis in the Global Phase 3 FIERCE-HN Study	CI
14/01	AVEO Oncology Announces First Patient Dosed in Front-Line AML Combination Study of Ficlatuzumab	CI
18/25/18	AVEO Oncology Presents Two Posters for Tivozanib at the 2025 ASCO GU Meeting	CI
16/24/16	AVEO Pharmaceuticals, Inc. Presents TiNivo-2 Results and TIVO-3 Exploratory Post Immunotherapy Survival Analysis at ESMO 2024	CI
18/24/18	Aveo Oncology Announces Phase 3 Renal Cell Carcinoma Clinical Trial (TiNivo-2) Results	CI
13/24/13	LG Chem Company and AVEO Oncology Announce LG Chem's First Proprietary Anti-Cancer Compound Enters Phase 1 Clinical Study, Dosing Initiated in the U.S	CI
25/24/25	AVEO Pharmaceuticals, Inc. Announces Executive Changes	CI
06/24/06	Aveo Oncology Announces Publication of Long-Term Survival in Patients with Relapsed/Refractory Advanced Renal Cell Carcinoma Treated with Tivozanib: Analysis of the Phase Iii Tivo-3 Trial in the Oncologist	CI
16/24/16	AVEO Oncology Enrolls First Patient in Pivotal FIERCE-HN Clinical Trial to Evaluate Ficlatuzumab in Combination with ERBITUX® in Patients with HPV-negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)	CI
27/23/27	AVEO Oncology Announces Completion of Enrollment in Pivotal Phase 3 TiNivo-2 Study of FOTIVDA(R) in Combination with OPDIVO(R) in Advanced Renal Cell Carcinoma	CI

More news

Analysts' recommendations: AVEO Pharmaceuticals, Inc.

08/22/08	Stifel Downgrades AVEO Pharmaceuticals to Hold From Buy, Price Target is $15	MT
31/22/31	JonesTrading Downgrades AVEO Pharmaceuticals to Hold From Buy With $15 Price Target	MT
24/22/24	SVB Securities Downgrades AVEO Pharmaceuticals to Market Perform From Outperform, Retains Price Target at $15	MT
19/22/19	Baird Downgrades AVEO Pharmaceuticals to Neutral From Outperform, Adjusts Price Target to $15 From $17	MT
19/22/19	HC Wainwright Downgrades AVEO Pharmaceuticals to Neutral From Buy, Lowers Price Target to $15 From $19	MT

More recommendations

Press Releases: AVEO Pharmaceuticals, Inc.

20/23/20	AVEO PHARMACEUTICALS, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
20/23/20	LG Chem Completes Acquisition of AVEO Oncology	GL
18/23/18	AVEO Pharmaceuticals : Merger Agreement - Form 8-K	PU
18/23/18	AVEO PHARMACEUTICALS, INC. : Other Events (form 8-K)	AQ
06/23/06	AVEO Oncology Stockholders Approve Acquisition by LG Chem	GL

More press releases

News in other languages: AVEO Pharmaceuticals, Inc.

19/22/19	MÄRKTE ASIEN/China-Börsen schwach - Parteitag der KP enttäuscht
19/22/19	MÄRKTE ASIEN/China-Börsen hinken wieder hinterher
06/17/06	AVEO Pharmaceuticals : Oncology et EUSA Pharma annoncent des résultats prometteurs de la Phase 1 de l’étude de Phase 1/2 TiNivo sur le tivozanib et le nivolumab dans le traitement du carcinome à cellules rénales
06/17/06	AVEO Pharmaceuticals : Oncology und EUSA Pharma melden vielversprechende Phase-1-Ergebnisse aus der Phase-1/2-Studie TiNivo zu Tivozanib und Nivolumab bei Nierenzellkarzinom
23/17/23	AK Steel : Les valeurs à suivre à Wall Street

More news

Managers and Directors: AVEO Pharmaceuticals, Inc.

Manager	Title	Age	Since
Michael Ferraresso CEO	Chief Executive Officer	-	01/07/2026
Jinchul Jeong DFI	Director of Finance/CFO	-	-
Greg Oehrtman CTO	Chief Tech/Sci/R&D Officer	-	01/08/2022

Director	Title	Age	Since
Michael Bailey BRD	Director/Board Member	60	30/06/2026
Michael Ferraresso BRD	Director/Board Member	-	01/07/2026
Jinchul Jeong BRD	Director/Board Member	-	-

More insiders

AVEO Pharmaceuticals, Inc. is an oncology-focused biopharmaceutical company. The Company is focused on delivering medicines for patients with cancer. The Company's commercial product include FOTIVDA (tivozanib), which is an oral, vascular endothelial growth factor receptor (VEGFR) and tyrosine kinase inhibitor (TKI). The Company markets FOTIVDA (tivozanib) in the United States for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. It also develops FOTIVDA in immuno-oncology combinations in refractory RCC and other indications and has several other investigational programs in clinical development. The Company's pipeline of product candidates includes ficlatuzumab, AV-380, AV-203 and AV-353. Its ficlatuzumab is a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor (HGF).

Employees

114

Sector

Pharmaceuticals

More about the company

Stock Market
Stocks
AVEO Stock

The best tools reserved for subscribers to boost the performance of your investments!

Date	Insider	Type	Main position	Quantity	% Market Cap.
19/01/23	Anthony Evnin	Issuer sale	Director	1,10,043	0.3166%
19/01/23	Corinne Epperly	Issuer sale	Director	47,500	0.1366%
19/01/23	Jebediah Ledell	Issuer sale	Chief Operating Officer	1,97,702	0.5687%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AVEO PHARMACEUTICALS, INC.	-.--%	+0.20%	-	-	52Cr
ELI LILLY AND COMPANY	+2.83%	+4.40%	+60.84%	+123.50%	1,16500Cr
JOHNSON & JOHNSON	+3.81%	+5.66%	+38.70%	+74.91%	64TCr
ABBVIE INC.	+0.14%	+0.63%	+24.71%	+95.03%	50TCr
ROCHE HOLDING AG	-0.40%	+2.90%	+43.67%	+64.26%	38TCr
MERCK & CO., INC.	-1.76%	+1.41%	+68.06%	+43.41%	36TCr
NOVARTIS AG	-0.40%	+3.00%	+22.89%	+52.00%	30TCr
ASTRAZENECA PLC	-1.67%	+2.62%	+2.21%	+26.46%	27TCr
AMGEN INC.	+2.04%	+3.05%	+51.12%	+60.42%	24TCr
GILEAD SCIENCES, INC.	+2.36%	-0.11%	+29.42%	+102.04%	19TCr
Average	-0.21%	+2.54%	+37.96%	+71.34%	45.06TCr
Weighted average by Cap.	-0.19%	+3.17%	+43.11%	+83.11%

AVEO Pharmaceuticals, Inc. Share Price

Stocks